Albireo Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALBO Nasdaq 8731 https://albireopharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Albireo Pharma Inc

Why These Two Biotech Stocks Blasted Higher This Week - Jan 13th, 2023 11:15 pm
Biotechs CinCor, Albireo Jump on Takeovers by Larger Drugmakers - Jan 9th, 2023 9:11 pm
JPMorgan Health Conference Kicks Off With Predictable Flurry of (Small) Deals - Jan 9th, 2023 8:00 pm
Ipsen to buy liver disease drugmaker for $952M - Jan 9th, 2023 4:36 pm
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday - Jan 9th, 2023 4:00 pm
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline - Jan 9th, 2023 11:24 am
We're Not Very Worried About Albireo Pharma's (NASDAQ:ALBO) Cash Burn Rate - Dec 21st, 2022 3:54 pm
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 20th, 2022 9:30 pm
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA - Dec 19th, 2022 1:30 pm
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors - Dec 6th, 2022 1:30 pm
Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2 - Nov 30th, 2022 1:30 pm
Albireo Pharma (NASDAQ:ALBO) dips 16% this week as increasing losses might not be inspiring confidence among its investors - Nov 10th, 2022 11:41 am
Albireo to Participate in Jefferies London Healthcare Conference - Nov 9th, 2022 1:30 pm
Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates - Nov 8th, 2022 10:35 pm
Albireo Reports Q3 2022 Financial Results and Business Update - Nov 8th, 2022 9:01 pm
Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types - Nov 7th, 2022 1:30 pm
Albireo Announces 2022 SPARK Grant Winners - Nov 3rd, 2022 12:30 pm
Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia - Nov 2nd, 2022 12:30 pm
Earnings Preview: Celldex Therapeutics (CLDX) Q3 Earnings Expected to Decline - Nov 1st, 2022 2:01 pm
Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022 - Nov 1st, 2022 12:30 pm